Cibc World Markets Corp Buys Shares of 13,065 TG Therapeutics, Inc. (NASDAQ:TGTX)

Cibc World Markets Corp purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,065 shares of the biopharmaceutical company’s stock, valued at approximately $393,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp increased its holdings in TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after acquiring an additional 2,398,015 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics during the 4th quarter worth approximately $14,508,000. Braun Stacey Associates Inc. purchased a new stake in TG Therapeutics in the 4th quarter valued at approximately $13,328,000. Finally, Castellan Group acquired a new stake in TG Therapeutics during the 4th quarter valued at $8,539,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $42.99 on Monday. The business’s 50-day moving average price is $33.17 and its 200 day moving average price is $29.74. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.15. The company has a market capitalization of $6.75 billion, a PE ratio of -429.86 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

TGTX has been the subject of a number of analyst reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.50% of the stock is owned by company insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.